Delcath Systems, Inc. (NASDAQ:DCTH) Given Consensus Rating of “Moderate Buy” by Brokerages

Delcath Systems, Inc. (NASDAQ:DCTH) has earned an average recommendation of “Moderate Buy” from the six research firms that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average 12-month price target among analysts that have covered the stock in the last year is $22.40.

A number of research analysts recently issued reports on the company. Wall Street Zen upgraded Delcath Systems from a “hold” rating to a “buy” rating in a research note on Saturday, January 10th. BTIG Research reissued a “buy” rating and issued a $23.00 price objective on shares of Delcath Systems in a report on Tuesday, November 4th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Delcath Systems in a report on Monday, December 29th. HC Wainwright reiterated a “buy” rating and issued a $30.00 price target on shares of Delcath Systems in a research report on Friday, January 9th. Finally, Craig Hallum reiterated a “buy” rating and set a $20.00 price target on shares of Delcath Systems in a research note on Tuesday, October 21st.

Insider Buying and Selling at Delcath Systems

In other news, CEO Gerard J. Michel bought 11,500 shares of Delcath Systems stock in a transaction dated Tuesday, November 11th. The stock was bought at an average price of $8.53 per share, for a total transaction of $98,095.00. Following the purchase, the chief executive officer owned 330,834 shares of the company’s stock, valued at approximately $2,822,014.02. The trade was a 3.60% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 17.40% of the company’s stock.

Hedge Funds Weigh In On Delcath Systems

A number of large investors have recently made changes to their positions in the stock. USA Financial Formulas acquired a new stake in shares of Delcath Systems in the second quarter valued at about $25,000. California State Teachers Retirement System purchased a new position in Delcath Systems in the second quarter valued at about $26,000. Russell Investments Group Ltd. acquired a new stake in shares of Delcath Systems during the 3rd quarter valued at approximately $29,000. Tower Research Capital LLC TRC purchased a new stake in shares of Delcath Systems during the 2nd quarter worth approximately $40,000. Finally, Ameritas Investment Partners Inc. purchased a new stake in shares of Delcath Systems during the 2nd quarter worth approximately $42,000. Hedge funds and other institutional investors own 61.12% of the company’s stock.

Delcath Systems Price Performance

Shares of DCTH opened at $10.37 on Friday. Delcath Systems has a 1-year low of $8.12 and a 1-year high of $18.23. The stock has a market cap of $366.16 million, a PE ratio of 1,037.00 and a beta of 0.39. The firm has a fifty day moving average price of $9.75 and a 200 day moving average price of $10.53.

Delcath Systems (NASDAQ:DCTH) last issued its quarterly earnings data on Tuesday, November 4th. The company reported $0.02 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.02. Delcath Systems had a return on equity of 7.02% and a net margin of 1.50%.The company had revenue of $20.56 million for the quarter, compared to analyst estimates of $23.22 million. As a group, equities analysts expect that Delcath Systems will post -0.79 EPS for the current fiscal year.

Delcath Systems announced that its board has approved a stock buyback plan on Thursday, November 20th that authorizes the company to buyback $25.00 million in shares. This buyback authorization authorizes the company to purchase up to 8.6% of its shares through open market purchases. Shares buyback plans are often an indication that the company’s leadership believes its shares are undervalued.

Delcath Systems Company Profile

Delcath Systems, Inc is a specialty pharmaceutical and medical technology company focused on the development and commercialization of its proprietary Hepatic CHEMOSAT® Delivery System, designed to deliver high-dose chemotherapeutic agents directly to the liver while minimizing systemic exposure. The company’s core technology performs isolated hepatic perfusion, enabling oncologists to administer concentrated melphalan to patients with primary and metastatic liver tumors, including those arising from ocular melanoma.